公司介绍 – Wego Medical Systems Co., Ltd.

添加会员

求助

Wego Medical Systems Co., Ltd.

回首页

公司简介

产品橱窗

影音视听

寄出询问函

联络我们

	Recommended Results

公司介绍

Weigao Holding Company Limited. (“Weigao Holding”) and together with its subsidiaries (“Weigao”)is situated in Weihai City, a picturesque coastal city in China. Weigao Holding has 18 subsidiaries and has more than 9,000 employees and a total asset value of over RMB 4 billion (approximately US$0.59 billion). Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”), the major subsidiary of Weigao Holding, was listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited in 2004. Weigao covers a manufacturing area of 1,250,000 square meters including sterilized workshops with an area of 200,000 square meters that comply with GMP standards. It currently produces more than 250 types of medical products with more than 30,000 specifications.

In the past 20 years, Weigao rooted with the spirit of “development, innovation, pragmatism and consolidation”, and dedicated to attract talented people from the communities. Weigao focuses on technology driven innovative ideas and scientific management to transform the development mode and to advance the healthy and efficient growth of the business. In the domestic market, the company was the early mover to initiate the products of single use transfusion sets, medical suture, implantable medical catheters, coronary stents, intravenous catheters, irregular needles, blood purification, orthopaedic, electronic and mechanical medical products, medical injection fluid products, diagnostic reagents, artificial blood plasma and various medical products and medications. Weigao has established very large manufacturing bases in China for medical consumables, orthopaedic products, pharmaceuticals，and aerospace products. Today, Weigao is the leading single use medical consumable manufacturer in China.

Weigao established the mode of scientific management to achieve a smooth operation system. It is the first company in the industry to introduce and to successfully establish the management system of enterprise resource planning (ERP), key performance indicators (KPI) and other management system. Weigao Holding obtained the certifications of Conformité Européene (CE), ISO9000, ISO13485, China Compulsory Certification; and products registration of FDA 510K from Food and Drug Association (FDA). The award accredited to testing and inspection center of the company is also the only certification issued by China National Accreditation Board for Lab oratories in industry.

Weigao is devoted to innovation, technology and people and its commitment to technology is the value to its development. Weigao was accredited by the State Science and Technology Commission as the “Key High Technology & New Technological Enterprise under the State Torch Program”, the “Preferred Manufacturing Base for New Products Developed by the State High Technology Research Development (863) Program, and the technology center was also notarized by national governmental authorization as “State Enterprise Technology Center”. Weigao continues to develop into a conglomerate enterprise comprising of duties and responsibilities of manufacturing, education and research. The company established a post-doctoral research working center and collaborated with scientific research institutions and universities with strong scientific and research strength in setting up nine research and development centers. Ten academicians were appointed as consultants. There are more than 60 types of products which are further developed to enhance to an international level, and many of which filled the domestic blank. The company engaged in more than 20 national projects including Project 863, Project Torch, Model Project of National High Tech, The Key Technology Innovation Program of the State, and other projects. Currently, Weigao plays roles in the market of drug eluting stent (DES), pre-filled syringes and orthopedic material which were previously dominated by international players.

Weigao has been persistently sustain its brand value . The “Jierui” trademark is notarized by State Administration for Industry & Commerce as “China Famous Brand”; the “Jierui Single Use Sterile Infusion and Syringe Medical Device” was accredited by General Administration of Quality Supervision, Inspection and Quarantine of China as “the Most Famous Branded Product in China”; it is also notarized by China Brand Academy as “The No.1 Trademark” in the industry. Weigao has an extensive coverage of over 100 representative offices in 30 provinces, municipality and autonomous regions in China. Long term reliable relationship has also been well established with more than 7,000 hospitals, over 400 blood stations, and over 1800 other medical units. Today, Weigao’s products are not just the best-selling products in the domestic market; they are also exported to more than 50 countries and regions, including the United States, European countries, Russia, South Africa, and Brazil.

Weigao will continue to strive without reserve for the scientific development, and the mission is to “work with physicians to create healthy life for people in future”. Weigao will continue to improve and adjust the business structure, products mix and organizational structure. The goal of Weigao is to gradually transform from a domestic manufacturer to an internationally competitive, leading in Asia, and respectable conglomerate. Weigao, standing as a leading medical device company, continues to create and sustain a high level of performance in medical device products and pharmaceuticals. Weigao is well-positioned to continuing serving the medical community and improve people’s health for generations to come.